Related Experiment Video
Updated: Mar 15, 2026

Stromal Vascular Fraction-enriched Fat Grafting for the Treatment of Symptomatic End-neuromata
Published on: November 23, 2017
A weighted scoring system to differentiate malignant liposarcomas from benign lipomas
1Musculoskeletal Tumour Centre of Peking University People's Hospital, China & Department of Orthopaedic Surgery, Tan Tock Seng Hospital, Singapore.
A new scoring system using clinical and MRI features can differentiate malignant liposarcomas from benign lipomas. This tool accurately identifies malignant tumors with a high negative predictive value.
Area of Science:
- Oncology
- Radiology
- Medical Imaging
Background:
- Liposarcomas and lipomas are soft tissue tumors.
- Differentiating between malignant liposarcomas and benign lipomas can be challenging.
Purpose of the Study:
- To develop a scoring system for distinguishing malignant liposarcomas from benign lipomas.
- To utilize clinical and magnetic resonance imaging (MRI) features for differentiation.
Main Methods:
- Reviewed clinical and MRI features of 66 patients (32 malignant liposarcomas, 34 benign lipomas).
- Identified 5 key predictors: male gender, tumor size, deep location, septal/nodular features, and internal cystic changes.
- Constructed a weighted scoring system based on these predictors.
Main Results:
- The scoring system identified 5 strongest predictors of liposarcoma.
- A cut-off score of 35 correctly classified 32 malignant liposarcomas and 4 benign lipomas.
- Achieved a 100% negative predictive value for benign lipomas with a score ≤35.
Conclusions:
- A scoring system based on 5 clinical and MRI features effectively differentiates malignant from benign lipomatous tumors.
- Further validation in independent populations is recommended.
More Related Videos
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019